In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. (Q43220404)

16 November 2017

title

In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. (English)

1 reference

16 November 2017

Thomas M Polasek

1 reference

16 November 2017

Janani S Sadagopal

series ordinal

1 reference

16 November 2017

David J Elliot

series ordinal

1 reference

16 November 2017

John O Miners

series ordinal

1 reference

16 November 2017

publication date

11 December 2009

1 reference

European Journal of Clinical Pharmacology

16 November 2017

published in

1 reference

16 November 2017

1 reference

16 November 2017

1 reference

16 November 2017

page(s)

275-283

1 reference

The use of caffeine as a metabolic probe for human drug metabolizing enzymes

16 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-009-0760-2

Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment

21 January 2018

1 reference

12 December 2020

Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate

1 reference

12 December 2020

Pharmacokinetic drug interactions of macrolides

1 reference

12 December 2020

Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions

1 reference

12 December 2020

Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance

1 reference

12 December 2020

An in vitro approach to potential methadone metabolic-inhibition interactions

1 reference

12 December 2020

A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn

1 reference

12 December 2020

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

1 reference

12 December 2020

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation

1 reference

12 December 2020

Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds

1 reference

12 December 2020

Oxidative metabolism of zolpidem by human liver cytochrome P450S

1 reference

12 December 2020

Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole

1 reference

12 December 2020

Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro

1 reference

12 December 2020

Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants

1 reference

12 December 2020

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine

1 reference

12 December 2020

Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications

1 reference

12 December 2020

Rifampin reduces plasma concentrations and effects of zolpidem*

1 reference

12 December 2020

Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods

1 reference

12 December 2020

Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A

1 reference

12 December 2020

Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4

1 reference

12 December 2020

Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs

1 reference

12 December 2020

Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon

1 reference

12 December 2020

In vitro approaches to investigate mechanism-based inactivation of CYP enzymes

1 reference

12 December 2020

Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women

1 reference

12 December 2020

Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation

1 reference

12 December 2020

An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

1 reference

12 December 2020

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

1 reference

12 December 2020

Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations

1 reference

12 December 2020

Coadministration of short-term zolpidem with sertraline in healthy women

1 reference

12 December 2020

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction

1 reference

12 December 2020

The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America

1 reference

12 December 2020

Time-dependent CYP inhibition

1 reference

12 December 2020

An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

1 reference

12 December 2020

Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition

1 reference

12 December 2020

Comparison of different approaches to predict metabolic drug-drug interactions

1 reference

12 December 2020

S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.

1 reference

12 December 2020

The Simcyp population-based ADME simulator

1 reference

12 December 2020

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition

1 reference

12 December 2020

Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole

1 reference

12 December 2020

Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition

1 reference

12 December 2020

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

1 reference

12 December 2020

An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes

1 reference

12 December 2020

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

1 reference

12 December 2020

Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein

1 reference

12 December 2020

Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil

1 reference

12 December 2020

Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes

1 reference

12 December 2020

Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery

1 reference

12 December 2020

10.1007/S00228-009-0760-2

Identifiers

DOI

1 reference

16 November 2017

1 reference